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De Novo mtDNA nt 8993 (TrG) Mutation Resulting
in Leigh Syndrome
To the Editor:
Recently, Blok et al. (1997) analyzed mtDNA in oocytes
from an asymptomatic mother of three children exhib-
iting heteroplasmic expression of the mtDNA nt 8993
(TrG) (T8993G) mutation associated with Leigh syn-
drome (MIM 516060). The mother had 50% mutant
mtDNA in her blood. It was striking that one of the
seven oocytes analyzed showed no evidence of the mu-
tation, while the remaining six had a mutant load of
195%. Blok et al. suggested that this observation re-
flected preferential amplification of the mtDNA variant
during oogenesis. During formation of the zygote,
mtDNA is derived exclusively from the oocyte (Giles et
al. 1980). Thus, it is possible that a de novo mutation
may arise during oogenesis. A first carrier of a de novo
mutation may be a mother who exhibits mosaicism for
the mutation restricted to oocytes. However, it has been
shown by previous investigators that the mothers of pa-
tients with Leigh syndrome associated with the mutation
usually have substantial levels of the mutant mtDNA
(Tatuch et al. 1992; Santorelli et al. 1993; Tulinius et
al. 1995). The proportion of the mutant mtDNA in the
lymphocytes from such mothers has been reported to be
38%–76%. Here we report the case of a 1-year-old boy
with Leigh syndrome associated with the T8993G mu-
tation, whose mother did not have the mutant mtDNA
in her blood or urine sediment cells. It was shown that
a de novo T8993Gmutation in mtDNAmay occur spon-
taneously at a high level in oocytes, thereby causing
Leigh syndrome in the second generation.
The present patient was a Japanese boy born at term
after an uncomplicated pregnancy. He was the second
child of a 25-year-old mother and a 23-year-old father,
who were healthy and unrelated. A 3-year-old sister was
also healthy. His birth weight was 2,842 g, and the oc-
cipito-frontal circumference (OFC) was 33.2 cm (50th
percentile). Generalized hypotonia was noted at birth.
He developed apnea attacks and altered consciousness,
after upper respiratory infections at the ages of 2 and 4
mo. From the age of 7 mo, he showed symptoms of
brain-stem dysfunction, such as irregular respiration and
swallowing difficulty. At the age of 9 mo, growth re-
tardation (height 72.0 cm; body weight 6.84 kg, 2.3
kg SD) and microcephaly (OFC 43.0 cm, !10th percen-
tile) were obvious. Although he could follow objects
with his eyes and could respond to auditory stimuli, his
head control was poor, because of severe generalized
hypotonia.
Laboratory examination revealed increased lactate
and pyruvate levels in blood (lactate 28 mg/dl; pyruvate
2.0 mg/dl) and cerebrospinal fluid (lactate 50 mg/dl; py-
ruvate 2.7 mg/dl) with high lactate/pyruvate and b-hy-
droxybutyrate/acetoacetate (2.9; normal range 1.84
) ratios. Plasma amino acid analysis revealed an in-0.96
creased level of alanine (62.9 mmol/dl; normal range
16.9–48.3 mmol/dl). On arterial blood gas analysis, met-
abolic acidosis was noted with respiratory compensa-
tion, i.e., pH 7.37; carbon dioxide tension 26.8 mmHg;
partial pressure of oxygen 113.3 mmHg; bicarbonate
15.4 mEq/liter; and base excess 8.0 mEq/liter. Brain
magnetic-resonance images revealed symmetrical ne-
crotic foci in the striatum and periaqueductal gray mat-
ter, which are characteristic of Leigh syndrome.
Histological examination of biopsied quadriceps femoris
muscle showed variation in fiber size, but ragged-red
fibers were not seen. Electron microscopy, however,
showed a marked increase in the number of variably
sized mitochondria with aberrant cristae. The activities
of mitochondrial respiratory chain enzymes in the biop-
sied muscle were normal (NADH cytochrome c reduc-
tase 162.9 nmol/min/mg mitochondrial protein, control
; succinate cytochrome c reductase 139.8,27.3 11.6
control ; cytochrome c oxidase 63.9, control76.6 17.7
).33.0 16.1
After informed consent had been granted, blood and
urine samples for DNA extraction were obtained from
the patient and from his parents, sister, and maternal
grandmother. In addition, the patient’s DNA was also
extracted from muscle and skin fibroblasts. Because the
ratio of mutant to nonmutant mtDNA found in mito-
chondrial myopathy, encephalopathy, lactic acidosis,
and strokelike episodes associated with pathogenic point
mutations is not constant in lymphocytes and muscle
(Poulton and Morten 1993), we extracted mtDNA from
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Figure 1 Pedigree of the family and autoradiograph of AvaI-
digested 32P-labeled PCR products of mtDNA encompassing the ATP-
ase 6 gene. Template DNA was prepared from lymphocytes of family
members. In the proband, the 551-bp PCR product harboring the
mtDNA nt 8993 (TrG) mutation was cleaved into 345-bp and 206-
bp fragments. No mutant mtDNA was detected for the proband’s
parents, sister, or maternal grandmother.
at least two different somatic cells. DNA in lymphocytes,
muscle, and skin fibroblasts was extracted by the phenol/
chloroform method, although the procedure involving
proteinase K digestion/boiling treatment was required
for urine sediment cells. mtDNA encompassing the ATP-
ase 6 gene was amplified by PCR, by use of a pair of
primers, 5′-ccg act aat cac cac cca ac-3′ (nt 8648–8665)
and 5′-tgt cgt gca ggt aga ggc tt-3′ (nt 9180–9199). The
PCR conditions were as follows: 30 cycles, each con-
sisting of denaturation for 0.5 min at 95C, annealing
for 0.5 min at 55C, and extension for 0.5 min at 72C.
One extra cycle was then performed, after addition of
10 mCi of a-[32P]dATP (3,000 Ci/mmol), 10 pmol of each
primer, and 1.0 unit of Taq polymerase. Condition for
this last cycle were 5 min at 95C, 0.5 min at 55C, and
5 min at 72C. Adding radioactive dATP in only the last
PCR cycle avoids the formation of heteroduplex DNA
molecules, which would cause underestimation of the
mutant mtDNA levels after restriction-enzyme digestion
(Schoffner et al. 1990). Five microliters of the PCR prod-
uct were digested in a final volume of 20 ml for 1 h at
37C with 10 units of AvaI (Toyobo). The digestion
products were electrophoresed through a 10% nonden-
aturing polyacrylamide gel. The gel was dried and au-
toradiographed at room temperature for 1 h by use of
Kodak x-ray film. PCR restriction-digestion analysis of
mtDNA from the patient revealed a TrG change at nt
8993, creating a new AvaI restriction site (fig. 1). The
proportion of the mutant mtDNA was calculated as the
ratio between the intensity of the 551-bp band and that
of the 345-bp  206-bp bands, by use of a scanning
densitometer. The sensitivity of the PCR assay for the
mutation was 0.2%, which was determined by analyzing
serial dilutions of mutant mtDNA. The patient had
195% mutant mtDNA in all examined samples, includ-
ing lymphocytes, urine sediment cells, skeletal muscle,
and skin fibroblasts, but no mutant mtDNA was de-
tected in lymphocytes or urine sediment cells from the
mother, sister, or maternal grandmother.
Cases have been reported in which novel mtDNAmu-
tations in sporadic patients with mitochondrial en-
cephalomyopathy appeared to be confined only to skel-
etal muscle (Fu et al. 1996; Weber et al. 1997). It is
speculated that this phenomenon may reflect loss of the
mutation by random genetic drift in mitotic tissues and
proliferation of mitochondria containing the mutant
mtDNA in postmitotic cells. Although muscle for DNA
analysis was obtained only for the patient, it has been
reported that the proportion of the mutant mtDNA was
fairly constant in muscle and lymphocytes in patients
carrying the T8993G mutation (Ma¨kela¨-Bengs et al.
1995). Furthermore, the de novo occurrence of the
T8993G mutation has previously been described, but in
these families the amount of mutant mtDNA gradually
increased during several generations, before reaching
levels sufficiently high to cause Leigh syndrome (San-
torelli et al. 1993; Tulinius et al. 1995). The finding that
the mutation was present at high percentages in all sam-
ples from the patient but not in the mother or sister may
be interpreted as follows: the mutation occurred spon-
taneously in some, but not all, oocytes, and consequently
the mother’s ovary may have had a mosaic status for
the mutation, although it is not clear when the mutation
arose. The germ-line mosaicism for the T8993G muta-
tion identified by Blok et al. (1997) supports our inter-
pretation. The recurrence risk cannot be estimated cor-
rectly, whereas the germ-line mosaicism may lead to
familial clustering of affected individuals. We believe
that this observation is useful for genetic counseling for
families with affected patients.
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